ACRS

ACRS

Aclaris Therapeutics Inc. Common Stock

$1.535+0.000 (0.000%)

Precio en Tiempo Real

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$1.535

Máximo

$1.535

Mínimo

$1.535

Volumen

0.61M

Fundamentos de la Empresa

Estadísticas de Negociación

Noticias Relacionadas

GlobeNewswire

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today

Ver más
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
Analyst Upgrades

Wedbush Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $8

Wedbush analyst Martin Fan initiates coverage on Aclaris Therapeutics with a Outperform rating and announces Price Target of $8.

Ver más
Wedbush Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $8
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $16

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics with a Buy and lowers the price target from $20 to $16.

Ver más
HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $16
GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ

Ver más
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.